APA

Berwick D. C., Javaheri B., Wetzel A., Hopkinson M., Nixon-Abell J., Grannò S., Pitsillides A. A. & Harvey K. (20180222). Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling. : Molecular neurodegeneration.

Chicago

Berwick Daniel C, Javaheri Behzad, Wetzel Andrea, Hopkinson Mark, Nixon-Abell Jonathon, Grannò Simone, Pitsillides Andrew A and Harvey Kirsten. 20180222. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling. : Molecular neurodegeneration.

Harvard

Berwick D. C., Javaheri B., Wetzel A., Hopkinson M., Nixon-Abell J., Grannò S., Pitsillides A. A. and Harvey K. (20180222). Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling. : Molecular neurodegeneration.

MLA

Berwick Daniel C, Javaheri Behzad, Wetzel Andrea, Hopkinson Mark, Nixon-Abell Jonathon, Grannò Simone, Pitsillides Andrew A and Harvey Kirsten. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling. : Molecular neurodegeneration. 20180222.